Trademarks = 1

Forward Citations = 0

Loading Chart...

3 inventors (with patents filed for the assignee):

Yitshak Itsik Efrati (3 out of 3 patents)

Peter C Hoyle (1 out of 3 patents)

Paul Waymack (1 out of 2 patents)

4 patents: Sort by Forward Citations

1. 10945960 - Celecoxib and amlodipine formulation and method of making the same (2021-03-16),

2. 10925835 - Celecoxib and amlodipine formulation and method of making the same (2021-02-23),

3. 10350171 - Celecoxib and amlodipine formulation and method of making the same (2019-07-16),

4. 9662315 - Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs (2017-05-30),

Kitov Pharmaceuticals is a clinical-stage company focused on advancing first-in-class oncology drug candidates. Their lead product, NT219, is a novel dual inhibitor that targets key proteins involved in cancer cell survival and resistance. Kitov is dedicated to developing innovative therapies to address unmet medical needs in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

4 Patents

#246 in Tel Aviv

#1,353 in Israel

Tel Aviv, Israel

Kitov Pharmaceuticals

Forward Citations = 0

3 inventors:

Yitshak Itsik Efrati (3 out of 3 patents)

Peter C Hoyle (1 out of 3 patents)

Paul Waymack (1 out of 2 patents)

Please report any incorrect information to support@idiyas.com